Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

EyePoint Pharmaceuticals Inc (EYPT) USD0.001

Sell:$0.85 Buy:$0.85 Change: $0.0086 (1.00%)
Market closed |  Prices as at close on 1 June 2020 | Switch to live prices |
Change: $0.0086 (1.00%)
Market closed |  Prices as at close on 1 June 2020 | Switch to live prices |
Change: $0.0086 (1.00%)
Market closed |  Prices as at close on 1 June 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Contact details

480 Pleasant St Ste B300
United States
+1 (617) 9265000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$106.07 million
Shares in issue:
124.74 million
United States
US dollar

Key personnel

  • Goran Ando
    Independent Chairman of the Board
  • Nancy Lurker
    President, Chief Executive Officer, Director
  • George Elston
    Chief Financial Officer and Head of Corporate Development
  • Ron Honig
    Senior Vice President, General Counsel, Secretary
  • Dario Paggiarino
    Senior Vice President, Chief Medical Officer
  • Said Saim
    Chief Technology Officer
  • Scott Jones
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.